A 12-month open-label evaluation of the long-term safety of DVS-233 [desvenlafaxine] SR [sustained release] in outpatients with major depressive disorder.
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2009
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Wyeth
- 06 Jun 2007 New trial record.